Institute of Bioinformatics, International Technology Park, Bangalore560066, India.
Manipal Academy of Higher Education (MAHE), Manipal576104, Karnataka, India.
J Integr Bioinform. 2021 Mar 25;18(1):27-43. doi: 10.1515/jib-2021-0002.
The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people and claimed thousands of lives. Starting in China, it is arguably the most precipitous global health calamity of modern times. The entire world has rocked back to fight against the disease and the COVID-19 vaccine is the prime weapon. Even though the conventional vaccine development pipeline usually takes more than a decade, the escalating daily death rates due to COVID-19 infections have resulted in the development of fast-track strategies to bring in the vaccine under a year's time. Governments, companies, and universities have networked to pool resources and have come up with a number of vaccine candidates. Also, international consortia have emerged to address the distribution of successful candidates. Herein, we summarize these unprecedented developments in vaccine science and discuss the types of COVID-19 vaccines, their developmental strategies, and their roles as well as their limitations.
由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）大流行已经影响了数百万人，并夺走了数千人的生命。从中国开始，这可以说是现代最急剧的全球健康灾难。全世界都在奋起抗击这种疾病，而 COVID-19 疫苗是主要武器。尽管传统的疫苗开发管道通常需要十多年的时间，但由于 COVID-19 感染导致的每日死亡率不断上升，已经制定了快速通道策略，以便在一年内推出疫苗。政府、公司和大学已经联网，汇集资源，并提出了许多疫苗候选者。此外，还出现了国际财团来解决成功候选者的分配问题。在此，我们总结了疫苗科学方面的这些前所未有的发展，并讨论了 COVID-19 疫苗的类型、它们的开发策略以及它们的作用和局限性。
